Summary: Centessa Pharmaceuticals has made progress in its orexin receptor 2 agonist program, focusing on the development of treatments for sleep-wake disorders such as narcolepsy and idiopathic hypersomnia. The company has initiated a phase 1 clinical trial for ORX750, with … [Read more...]
Orexin-2 Receptor Agonist E2086 to Be Tested for Narcolepsy
Summary: Eisai Inc announced the registration and upcoming enrollment for Study E2086-A001-101, a clinical trial to evaluate the efficacy, safety, and tolerability of E2086, a novel selective orexin-2 receptor agonist, in adult patients with narcolepsy type 1. The trial, which … [Read more...]
NLS Pharmaceutics Secures Patent for Dual Orexin Receptor Agonists
Summary: NLS Pharmaceutics Ltd announced the publication of a new patent application by Aexon Labs with the World Intellectual Property Organization, introducing a novel series of dual orexin receptor agonists. These compounds are designed to treat narcolepsy and … [Read more...]
Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
Summary: Alkermes plc has launched the Vibrance-1 examine, a stage 2 medical trial to evaluate the basic safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in treating narcolepsy type 1. This oral treatment method aims to boost wakefulness by focusing on the … [Read more...]